Different from MET, HER2 can indirectly activate PI3K and amplification of HER2 appears to mutually exclusive with T790M in EGFR-mutated NSCLC patients who develop resistance (35, 49, 50). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.